WO2016196285A1 - Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) - Google Patents

Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) Download PDF

Info

Publication number
WO2016196285A1
WO2016196285A1 PCT/US2016/034645 US2016034645W WO2016196285A1 WO 2016196285 A1 WO2016196285 A1 WO 2016196285A1 US 2016034645 W US2016034645 W US 2016034645W WO 2016196285 A1 WO2016196285 A1 WO 2016196285A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgfr3
growth factor
factor receptor
fibroblast growth
therapies
Prior art date
Application number
PCT/US2016/034645
Other languages
English (en)
French (fr)
Inventor
Jan COSAERT
Dale L. Ludwig
Alan C. Rigby
Original Assignee
Imclone Llc
Immunogen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc, Immunogen, Inc filed Critical Imclone Llc
Publication of WO2016196285A1 publication Critical patent/WO2016196285A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2016/034645 2015-06-04 2016-05-27 Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) WO2016196285A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171007P 2015-06-04 2015-06-04
US62/171,007 2015-06-04

Publications (1)

Publication Number Publication Date
WO2016196285A1 true WO2016196285A1 (en) 2016-12-08

Family

ID=56137531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034645 WO2016196285A1 (en) 2015-06-04 2016-05-27 Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3)

Country Status (2)

Country Link
TW (1) TW201711702A (zh)
WO (1) WO2016196285A1 (zh)

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
WO2005012359A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
USRE39151E1 (en) 2000-08-18 2006-06-27 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US7411063B2 (en) 2005-11-08 2008-08-12 Immunogen, Inc. Process for preparation of maytansinol
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7598375B2 (en) 2005-08-09 2009-10-06 Millenium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US20100098696A1 (en) * 2008-10-20 2010-04-22 Haijun Sun Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US20110003969A1 (en) 2009-06-03 2011-01-06 Immunogen Inc. Conjugation methods
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20120253021A1 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US20120259100A1 (en) 2011-03-29 2012-10-11 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
WO2013083817A1 (en) * 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
WO2014193229A2 (en) * 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015094900A1 (en) * 2013-12-18 2015-06-25 Imclone Llc Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39151E1 (en) 2000-08-18 2006-06-27 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7368565B2 (en) 2001-05-31 2008-05-06 Immunogen Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005012359A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7598375B2 (en) 2005-08-09 2009-10-06 Millenium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US8383122B2 (en) 2005-08-24 2013-02-26 Immunogen, Inc. Process for preparing purified drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US7411063B2 (en) 2005-11-08 2008-08-12 Immunogen, Inc. Process for preparation of maytansinol
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20100098696A1 (en) * 2008-10-20 2010-04-22 Haijun Sun Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
US8043618B2 (en) 2008-10-20 2011-10-25 ImClone, LLC Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
US20110003969A1 (en) 2009-06-03 2011-01-06 Immunogen Inc. Conjugation methods
US20120259100A1 (en) 2011-03-29 2012-10-11 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
US20120253021A1 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2013083817A1 (en) * 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
WO2014193229A2 (en) * 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015094900A1 (en) * 2013-12-18 2015-06-25 Imclone Llc Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BURDON ET AL.: "Laboratory Techniques in Biochemistry and Molecular Biology", vol. 13, ELSEVIER SCIENCE PUBLISHERS
CAMPBELL: "Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas", 1984
CHOTHIA ET AL., J MOL BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
COLIGAN, J. ET AL.: "Current Protocols in Immunology", 2007, WILEY & SONS
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
JAIN NARESHKUMAR ET AL: "Current ADC Linker Chemistry", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 32, no. 11, 11 March 2015 (2015-03-11), pages 3526 - 3540, XP035553874, ISSN: 0724-8741, [retrieved on 20150311], DOI: 10.1007/S11095-015-1657-7 *
KABAT: "Sequences of Proteins of Immunological Interest, Fifth Edition,", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ( NIH PUBLICATION NO. 91-3242 )
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
LOHRISCH ET AL., SEMINARS IN ONCOLOGY, vol. 28, no. 6, 2001, pages 3 - 11
PREWETT M. ET AL., CANCER RES., vol. 59, 1999, pages 5209 - 5218
RITTER, A.: "Antibody-Drug Conjugates, Looking Ahead to an Emerging Class of Biotherapeutic", PHARMACEUTICAL TECHNOLOGY, January 2012 (2012-01-01), pages 42 - 47
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual, 2nd ed.,", 1989, COLD SPRING HARBOR LABORATORY PRESS
WITTE L. ET AL., CANCER METASTASIS REV., vol. 17, 1998, pages 155 - 161

Also Published As

Publication number Publication date
TW201711702A (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
NZ737471A (en) Hydrophilic linkers for conjugation
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12018500692A1 (en) Combination therapy for the treatment of cancer
MX2017002600A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
MY169147A (en) Drug-protein conjugates
WO2016046793A3 (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
NZ719936A (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
MY196747A (en) Cell injury inducing therapeutic drug for use in cancer therapy
WO2017062615A3 (en) Combination therapy for the treatment of cancer
EP3566710A4 (en) THERAPEUTIC AND USE OF IT IN MEDICINAL PRODUCTS FOR TREATMENT OF TUMORS AND / OR CANCER
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
SG11202108645YA (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
EP3978078A4 (en) COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16730572

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16730572

Country of ref document: EP

Kind code of ref document: A1